KDR and renal cell carcinoma: Doublet combination immunotherapy (immune checkpoint inhibitor [IO]/IO and IO/vascular endothelial growth factor receptor-tyrosine kinase inhibitor [VEGFR-TKI]) is now the standard front-line treatment for advanced renal cell carcinoma (RCC).